Leukaemia, Lymphocytic, Chronic — Ofatumumab With Fludarabine and Cyclophosphamide in B-CLL Patients
Citation(s)
An Open-labeled, Randomized, Two-dose, Parallel Group Trial of Ofatumumab, a Fully Human Monoclonal Anti-CD20 Antibody, in Combination With Fludarabine and Cyclophosphamide, in Patients With Previously Untreated B-cell CLL